JP2010505428A - 癌及び癌転移の治療と診断のための組成物及び方法 - Google Patents
癌及び癌転移の治療と診断のための組成物及び方法 Download PDFInfo
- Publication number
- JP2010505428A JP2010505428A JP2009531763A JP2009531763A JP2010505428A JP 2010505428 A JP2010505428 A JP 2010505428A JP 2009531763 A JP2009531763 A JP 2009531763A JP 2009531763 A JP2009531763 A JP 2009531763A JP 2010505428 A JP2010505428 A JP 2010505428A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- tpte
- cancer
- protein
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 206
- 201000011510 cancer Diseases 0.000 title claims abstract description 145
- 238000000034 method Methods 0.000 title claims abstract description 88
- 206010027476 Metastases Diseases 0.000 title claims abstract description 69
- 230000009401 metastasis Effects 0.000 title claims abstract description 59
- 238000011282 treatment Methods 0.000 title description 18
- 239000000203 mixture Substances 0.000 title description 16
- 238000003745 diagnosis Methods 0.000 title description 5
- 230000008883 metastatic behaviour Effects 0.000 claims abstract description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 322
- 102000039446 nucleic acids Human genes 0.000 claims description 273
- 108020004707 nucleic acids Proteins 0.000 claims description 273
- 101000679365 Homo sapiens Putative tyrosine-protein phosphatase TPTE Proteins 0.000 claims description 233
- 102100022578 Putative tyrosine-protein phosphatase TPTE Human genes 0.000 claims description 227
- 108090000623 proteins and genes Proteins 0.000 claims description 166
- 210000004027 cell Anatomy 0.000 claims description 163
- 102000004169 proteins and genes Human genes 0.000 claims description 146
- 230000014509 gene expression Effects 0.000 claims description 130
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 125
- 108020004459 Small interfering RNA Proteins 0.000 claims description 113
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 102
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 101
- 239000002773 nucleotide Substances 0.000 claims description 60
- 125000003729 nucleotide group Chemical group 0.000 claims description 60
- 239000003795 chemical substances by application Substances 0.000 claims description 58
- 108020004999 messenger RNA Proteins 0.000 claims description 51
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 49
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 45
- 238000005259 measurement Methods 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 36
- 210000001519 tissue Anatomy 0.000 claims description 34
- 108091034117 Oligonucleotide Proteins 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 31
- 239000012472 biological sample Substances 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 230000000692 anti-sense effect Effects 0.000 claims description 28
- 239000000523 sample Substances 0.000 claims description 28
- 230000000295 complement effect Effects 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 238000001514 detection method Methods 0.000 claims description 18
- 206010006187 Breast cancer Diseases 0.000 claims description 15
- 208000026310 Breast neoplasm Diseases 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 239000003184 complementary RNA Substances 0.000 claims description 13
- 108020005544 Antisense RNA Proteins 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 230000001875 tumorinhibitory effect Effects 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 230000006399 behavior Effects 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 230000003211 malignant effect Effects 0.000 abstract description 8
- 238000004393 prognosis Methods 0.000 abstract description 5
- 239000004055 small Interfering RNA Substances 0.000 description 99
- 229920002477 rna polymer Polymers 0.000 description 56
- 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 30
- 210000004881 tumor cell Anatomy 0.000 description 28
- 101710097446 3'(2'),5'-bisphosphate nucleotidase 1 Proteins 0.000 description 27
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 27
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 23
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 230000027455 binding Effects 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 17
- 102000053602 DNA Human genes 0.000 description 17
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 17
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 17
- 239000000539 dimer Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 230000001413 cellular effect Effects 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 230000003321 amplification Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 230000011987 methylation Effects 0.000 description 11
- 238000007069 methylation reaction Methods 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 101150066398 CXCR4 gene Proteins 0.000 description 8
- 101150001023 TPTE gene Proteins 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 230000035605 chemotaxis Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 230000030279 gene silencing Effects 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 102000051561 human TPTE Human genes 0.000 description 7
- -1 mRNA Chemical class 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108091030071 RNAI Proteins 0.000 description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000002975 chemoattractant Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 125000002652 ribonucleotide group Chemical group 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 5
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 5
- 230000007067 DNA methylation Effects 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091007960 PI3Ks Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
- 108091028664 Ribonucleotide Proteins 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000008045 co-localization Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000002336 ribonucleotide Substances 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 108091081021 Sense strand Proteins 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000034196 cell chemotaxis Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000010232 migration assay Methods 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 108010081589 Becaplermin Proteins 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108020004394 Complementary RNA Proteins 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 206010015866 Extravasation Diseases 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 102000016397 Methyltransferase Human genes 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 229960000975 daunorubicin Drugs 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000036251 extravasation Effects 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000003358 metastasis assay Methods 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 150000003906 phosphoinositides Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108091027075 5S-rRNA precursor Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 102000002110 C2 domains Human genes 0.000 description 2
- 108050009459 C2 domains Proteins 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 2
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100497623 Homo sapiens CXCR4 gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000010002 chemokinesis Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000010820 immunofluorescence microscopy Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229940107698 malachite green Drugs 0.000 description 2
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 210000001243 pseudopodia Anatomy 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101100297694 Arabidopsis thaliana PIP2-7 gene Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000935623 Homo sapiens 3'(2'),5'-bisphosphate nucleotidase 1 Proteins 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- OIRFJRBSRORBCM-UHFFFAOYSA-N Iopanoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(N)=C1I OIRFJRBSRORBCM-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 101150118523 LYS4 gene Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101000935589 Mus musculus Flavin reductase (NADPH) Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100456541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MEC3 gene Proteins 0.000 description 1
- 101100483663 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UFD1 gene Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- KTVKGXZZBQCBGD-UHFFFAOYSA-M Tyropanoate sodium Chemical compound [Na+].CCCC(=O)NC1=C(I)C=C(I)C(CC(CC)C([O-])=O)=C1I KTVKGXZZBQCBGD-UHFFFAOYSA-M 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HVZGHKKROPCBDE-HZIJXFFPSA-L chembl2068725 Chemical compound [Ca+2].CN(C)\C=N\C1=C(I)C=C(I)C(CCC([O-])=O)=C1I.CN(C)\C=N\C1=C(I)C=C(I)C(CCC([O-])=O)=C1I HVZGHKKROPCBDE-HZIJXFFPSA-L 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 102000053523 human CXCR4 Human genes 0.000 description 1
- 102000050103 human PIP Human genes 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 229960002979 iopanoic acid Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000030505 negative regulation of chemotaxis Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003907 phosphatidylinositol monophosphates Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108700028325 pokeweed antiviral Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960003037 sodium tyropanoate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
Abstract
Description
(i)TCGGTACTTGATAACATTACA(配列番号15)
(ii)CAGACTTGTGTTATTCTAGCA(配列番号18)
(iii)CTGAAATATGTTCAACTGCAA(配列番号21)
(iv)CAGATTGGCAACCAAGACTAA(配列番号24)
(v)AACCCTGCCACATGTTCATAT(配列番号27)
(vi)AATGACAGTCCACAGACAAGT(配列番号30)
(vii)AAGCTGATAAGAAGGCGGGTT(配列番号33)
gguacuugauaacauuacaTT
AGccaugaacuauuguaaugu
である。
gacuuguguuauucuagcaTT
GTcugaacacaauaagaucgu
である。
gaaauauguucaacugcaaTT
GAcuuuauacaaguugacguu
である。
gauuggcaaccaagacuaaTT
GTcuaaccguugguucugauu
である。
cccugccacauguucauauTT
TTgggacgguguacaaguaua
である。
ugacaguccacagacaaguTT
TTacugucaggugucuguuca
である。
gcugauaagaaggcggguuTT
TTcgacuauucuuccgcccaa
である。
アミノ酸欠失変異体は、配列からの1又はそれ以上のアミノ酸の除去を特徴とする。
1.低分子脂肪族、非極性又はわずかに極性の残基:Ala、Ser、Thr(Pro、Gly)
2.負の電荷を有する残基及びそれらのアミド:Asn、Asp、Glu、Gln
3.正の電荷を有する残基:His、Arg、Lys
4.高分子脂肪族、非極性残基:Met、Leu、Ile、Val(Cys)
5.高分子芳香族残基:Phe、Tyr、Trp。
抗体はまた、特定タンパク質又はペプチドを発現する細胞及び組織を示すために特異的診断物質に結合され得る。
抗体はまた、特定治療物質に結合され得る。
適切な非経口的投与経路は、血管内投与(例えば静脈内ボーラス注射、静脈内点滴、動脈内ボーラス注射、動脈内点滴及び血管系へのカテーテルによる点滴注入);組織周囲及び組織内投与(例えば腫瘍周囲及び腫瘍内注射);皮下注射又は皮下注入(浸透圧ポンプなどによる)を含む埋め込み(deposition);例えばカテーテル又は他の配置手段(例えば坐薬又は多孔性、無孔性又はゼラチン状物質を含むインプラント)による、疾患領域の部位又は前記部位の付近への直接(例えば局所)適用;及び吸入を含む。
組織及び細胞株
この試験は地域の倫理委員会("Ethikkommission der Arztekammer des Landes Rheinland−Pfalz")によって承認された。組換えDNA作業は、正式な許可を得て、Rheinland−Pfalzの州政府の規則に従って実施された。組織は、常套的な診断又は治療手順の間のヒト余剰材料から入手し、使用時まで−80℃で保存した。異なる記載がない場合、細胞株は商業的供給業者から入手した。脱メチル化試験のために、細胞を20−30%の集密度に分け、2μM又は10μM 5−アザ−2'−デオキシシチジン(5−アザ−dC)(Sigma−Aldrich)と共に72時間培養した。結腸癌細胞株HCT116WT、HCT116DNMT1−/−、HCT116DNMT3b−/−及びHCT116DKOはBert Vogelsteinの好意によって提供された。
RNAの抽出、一本鎖cDNAの合成、RT−PCR及びリアルタイムRT−PCRは以前に述べられているように実施した(Koslowski,M.et al.,Cancer Res.62,6750−6755(2002),Koslowski,M.et al.,Cancer Res.64,5988−5993(2004))。TPTEについての特異的プライマー対を設計するため、すべての相同体及び偽遺伝子を整列させた。無作為に選択した増幅産物の配列決定によって特異性を確認した。最終的な分析のために、TPTE特異的オリゴヌクレオチド(センス5'−TGG ATG TCA CTC TCA TCC TTG−3';アンチセンス5'−CCA TAG TTC CTG TTC TAT CTG−3'、63°Cアニーリング)を35サイクルのRT−PCRにおいて使用した。リアルタイム定量的発現分析は、TPTE特異的オリゴヌクレオチド(センス5'−GAG TCT ACA ATC TAT GCA GTG−3';アンチセンス5'−CCA TAG TTC CTG TTC TAT CTG−3'、63°Cアニーリング)を40サイクルのPCRで使用して3回実施した。18sRNA(センス5'−CGA TGC TCT TAG CTG AGT GTC−3';アンチセンス5'−TAA CCA GAC AAA TCG CTC CAC−3'、65°Cアニーリング)に対して正規化した後、腫瘍試料中のTPTE転写産物をΔΔCT法の計算を用いて正常組織と比較して数量化した。
TPTEのN末端(アミノ酸1〜51)に対して惹起したポリクローナル抗血清pAK2091を、カスタム抗体サービス(SeqLab)によって作製した。スライドをクエン酸緩衝液(pH6)中で15分間煮沸し、次に室温で15分間冷却することによる抗原の回収後、ホルマリン固定し、パラフィン包埋した組織切片に関して免疫組織化学を実施した。ウエスタンブロット分析のために、Triton−Xで溶解した細胞から抽出した全タンパク質60μgを使用した。抽出物を還元試料緩衝液(Roth)に希釈し、SDS−PAGEに供して、その後PVDF膜(Pall)に電気移動させた。HER2/neu(Abcam)に対して反応性の抗体を免疫染色するため、pAKT(細胞シグナル伝達)、AKT(細胞シグナル伝達)及びβ−アクチン(Abcam)を使用し、次いでホースラディッシュペルオキシダーゼ結合ヤギ抗マウス及びヤギ抗ウサギ二次抗体(Dako)を使用した。抗ウサギEnvision+ System(Dako)を製造者の指示に従って使用して、抗TPTE pAK2091一次抗体の検出を実施した。
2つのHindIII部位を導入してTPTEのオープンリーディングフレームを増幅した(センスプライマー5'−GAG AGA AAG CTT CCA CCA TGA ATG AAA GTC CTG ATC CCA CTG ACC T−3'、アンチセンスプライマー5'−GAG AGA AAG CTT GAT CGG ATC CAG CTA CAA CAT CAC TGC AAG TC−3')。増幅したフラグメントをベクターpEGFP−C1及びpEGFP−N3(BD Biosciences)に連結した。ホスファターゼドメインの活性部位に突然変異を担持する変異体TPTEC338Sを、PCRを介した部位指定突然変異誘発によって生成した。
ベクター構築物でのトランスフェクション後、内因性に又は外因性にTPTEを発現する細胞をスライド上で12〜24時間増殖させ、2%パラホルムアルデヒド/0.1%サポニン/PBSで固定した。TPTEについての間接免疫蛍光染色を、pAK2091ポリクローナルウサギ抗血清及び蛍光標識二次抗ウサギIgG抗体で実施した。F−アクチンとTPTEの共局在を分析するため、透過処理し固定した細胞をローダミン−ファロイジン(Molecular Probes)で染色した。タンパク質−タンパク質相互作用による膜結合PIP2及びPIP3の視覚化のためのPLC−δ1及びAKTのeGFP標識PHドメインについての発現プラスミドは、それぞれMario.J.Rebecchi及びJulian Downwardの好意によって提供された。カバースリップをSlow−Fade(Molecular Probes)のスライドに載せ、免疫蛍光顕微鏡検査によって分析した。
eGFP融合タンパク質を発現する細胞を、1%Triton X−100及びプロテアーゼ阻害剤(8μMロイペプチン、3.3μMキモスタチン2.9μMペプスタチンA、1mM AEBSF塩酸塩)を含む緩衝液に溶解した。溶解産物を4℃で5分間遠心沈殿させた。プレクリアのために、溶解産物をプロテインAセファロースCL−4B(Sigma−Aldrich)と共に4℃で1時間インキュベートした。プレクリアした溶解産物を抗eGFP抗体(Delta Biolabs)と共に4℃で2時間インキュベートし、次いでプロテインAセファロースCL−4Bと共に4℃で1時間インキュベートして、2分間の遠心分離によって沈殿させた。免疫複合体をIP緩衝液(50mM HEPES(pH7.5)、150mM NaCl)で洗浄し、反応緩衝液(100mM HEPES(pH7.5)、150mM NaCl、10mM DTT)に再懸濁した。タンパク質をSDS−PAGEによって分離し、免疫ブロット法によって分析した。
ホスファターゼ活性を測定するため、PTENとTPTEの融合タンパク質を免疫沈降させ、110μMの水溶性リン酸ホスファチジルイノシトール(Echelon)を含む反応緩衝液中、37℃で90分間インキュベートした。基質から放出されたリン酸塩の量を、マラカイトグリーンアッセイ(Echelon)を用いて測定した。15分間の呈色後、試料の吸光度をTecan Safireリーダーにて620nmで測定した。各々の試料を3回ずつ分析した。
siRNA二量体を共通規則に従って設計し、Ambionより購入した。TPTE siRNA二量体(センス5'−r(GGU ACU UGA UAA CAU UAC A)dTdT−3'、アンチセンス5'−r(UGU AAU GUU AUC AAG UAC C)dGdA−3')は、TPTE mRNA配列のヌクレオチド1722−1742(NM_013315)を標的した。対照として、スクランブルsiRNA二量体(センス5'−r(UAA CUG UAU AAU CGA CUA G)dTdT−5'、アンチセンス5'−r(CUA GUC GAU UAU ACA GUU A)dGdA−3')を使用した。TPTEサイレンシング試験のために、RNAiFectトランスフェクション試薬(Qiagen)を製造者の指示に従って使用して、細胞を100nm siRNA二量体でトランスフェクトした。すべての機能的アッセイを、siRNA二量体でのトランスフェクションの24時間後に実施した。すべての結果を、ヌクレオチド2487−2505を標的する2番目のセットのTPTE siRNA二量体(センス5'−r(GAU UGG CAA CCA AGA CUA A)dTdT−3'、アンチセンス5'−r(UAA GUC UUG GUU GCC AAU C)dTdG−3')で再現した。PTENサイレンシングのための二量体(5'−r(GGC GUA UAC AGG AAC AAU A)dTdT−3'、アンチセンス5'−r(UAU UGU UCC UGU AUA CGC C)dTdT−3')は、ヌクレオチド1161−1179(NM_000314)を対象とした。
実験の前に無血清培地で12時間培養した細胞を使用して、8.0μm多孔膜を備えるトランスウエルチェンバー(BD Biosciences)において細胞移動アッセイを実施した。siRNA実験のために、上述したようなsiRNA二量体でのトランスフェクションの24時間後に細胞を無血清条件に移した。無血清培地400μl中の4×104細胞をチェンバー上部に加えた。チェンバー下部には、FCS、PDGF−BB(Sigma−Aldrich)又はSDF−1α/CXCL12(R&D Systems)のいずれかを化学誘引物質として添加した培地800μlを入れた。24時間後、膜の底部側に移動した細胞を氷冷メタノール中で固定した;膜を切り出し、顕微鏡のスライド上に置いて、蛍光顕微鏡検査のためにHoechst(Dako)で標本を作製した。5つの無作為な視野内の細胞を(100×倍率)各々の膜について計数した。すべての実験を3回ずつ実施した。細胞のケモキネシスへの作用を、(i)チェンバーの上部及び下部に化学誘引物質を添加せずに、及び(ii)チェンバーの上部と下部の両方に化学誘引物質を添加して、同じ実験設定を用いて分析した。
siRNA二量体でのトランスフェクションの24時間後に1×104細胞を、様々な濃度のFCSを添加した培地で48時間培養した。Wallac Victor2マルチラベルカウンター(Perkin Elmer)で、DELFIA細胞増殖キット(Perkin Elmer)を製造者に指示に従って使用して、新たに合成されたDNA鎖へのBrdUの組込みを測定することによって増殖を分析した。
様々な濃度のFCSを添加した培地で細胞を培養し、48時間後に採取して、ヨウ化プロピジウムで染色した後、フローサイトメトリーDNA含量分析に供した。アポトーシス細胞及び細胞周期のS/G2/M期の細胞を、CellQuest−Software(Becton Dickinson)を用いて定量した。
インビボでの腫瘍増殖の分析のために、5×106細胞(NIH3T3−her2、NIH3T3−her2−eGFP、NIH3T3−her2−TPTE−eGFP及びNIH3T3−her2−TPTEC338S−eGFP)をNOD/SCIDマウスの側腹部に皮下注射した(各群につき5匹)。腫瘍をカリパス定規で定期的に測定し、腫瘍容積を計算した(V=a×b×b/2)。腫瘍細胞溢出の評価のために、CFSE(Vybrant CFDA SE Cell Tracer Kit;Molecular probes)で標識した1×106細胞をNOD/SCIDマウスの尾静脈に注入した(各群につき3匹)。6時間後にマウスを犠死させ、Hoechst 33258で標識した肺の凍結切片(20μM)を、蛍光顕微鏡検査によって溢出腫瘍細胞に関して分析した。各肺につき50の無作為な視野内の腫瘍細胞を計数した。
患者の転移率に関する腫瘍内でのTPTE及びCXCR4発現の統計分析を、SPSSソフトウエア(フィッシャーの直接確率検定)を用いて実施した。
TPTE mRNA発現を多数の正常及び新生物組織標本セットにおいて検討した。TPTE発現は精巣に限定され、他のすべての正常組織標本では、転写産物の量は高感度RT−PCRの検出限界未満である(図1a、b)。これに対し、155の腫瘍試料のうち59(38%)では悪性黒色腫(50%)、乳癌腫(47%)及び肺癌腫(55%)を含む種々の型の癌にわたって、並びに多数の癌細胞株セットにおいて(62%)、強いTPTE発現が検出された(表1)。
TPTEは、そのホモログであるPTENの脂質ホスファターゼ活性のために必須であり、十分であることが示されている、ホスファターゼ並びに脂質結合C2ドメインを含む(Lee,J.O.et al.,Cell 99,323−334(1999))。PIP3及びPI(3,4)P2に対して基質特異性を有する脂質ホスファターゼ活性が以前にTPTEのマウスオーソログに関してインビトロで示されたが(Wu,Y.et al.,J.Biol.Chem.276,21745−21753(2001))、ヒト対応物については酵素活性が検出されず(Walker,S.M.et al.,Biochem.J.360,277−283(2001))、PTENがこれまでのところ唯一の公知のヒトPIP3−ホスファターゼである。後者の試験は細菌起源の組換えタンパク質を使用したので、真核生物によってタンパク質を生産してヒトTPTEの酵素活性を再評価した。eGFPに融合したTPTE及びPTENのホスファターゼ及びC2ドメインをHEK−293細胞において発現させ、抗eGFP抗体結合プロテインAビーズでの免疫沈降によってタンパク質を精製し、マラカイトグリーンアッセイにおいて使用した。eGFP又は、推定上のホスファターゼ活性のために必須の部位で突然変異したTPTE変異体であるTPTEC338S−eGFPでトランスフェクトした細胞から得た等モル量の免疫沈降物を、同時精製ホスファターゼによる汚染を排除するための対照として使用した。驚くべきことに、TPTEはPTENに匹敵し得る割合でPIP3からリン酸塩を特異的に放出するが、それぞれの対照は放出しないことが認められた(図2a)。ヒト癌におけるTPTEの異常活性化と合わせてこの所見は、TPTEが腫瘍細胞におけるホスホイノシチドを介した形質膜シグナル伝達に関与することを示す。
腫瘍関連ホスファターゼTPTEを内因性発現する乳癌、前立腺癌及び悪性黒色腫細胞株において、低分子干渉RNA(siRNA)が誘導するTPTEの遺伝子サイレンシングの作用を分析した。定量的RT−PCR及びウエスタンブロット法は、TPTE特異的siRNA二量体が、細胞PTENレベルには影響を及ぼさずにTPTE転写産物及びタンパク質の堅固なノックダウンを誘導することを明らかにした(図3a)。
TPTE特異的siRNA二量体は、トランスウエル遊走アッセイ及びケモカインに基づく浸潤アッセイにおいて試験したすべての腫瘍細胞株においてPDGF又はSDF−1/CXCL12勾配への腫瘍細胞遊走を低下させるが、対照二量体は低下させない(図4a)。
EGF及びPDGFのような増殖因子受容体又はCXCR4及びCCR7などのケモカイン受容体によって媒介される走化性は、腫瘍の浸潤及び転移を促進する(Muller,A.et al.,Nature 410,50−56(2001),Staller,P.et al.,Nature 425,307−311(2003))。転移におけるTPTEの影響を検討するため、走化性によって媒介される癌細胞の転移播種のための重要な工程である、腫瘍細胞の溢出(Chambers,A.F.,Groom,A.C.& MacDonald,I.C.,Nat.Rev.Cancer 2,563−572(2002))を検討した。siRNAで処置した発蛍光団標識MDA−MB−231又はMCF−7乳癌細胞をNOD/SCIDマウスの尾静脈に注射した。6時間後に動物を犠死させ、肺に溢出した腫瘍細胞の数を全載肺切片において蛍光顕微鏡検査によって定量した。両方の腫瘍細胞株について、siRNAを介したTPTEのノックダウンは溢出細胞の数を有意に低下させた(図5a)。ヒトマイクロサテライト特異的PCRによる、転移形成性乳癌(MDA−MB−231、MCF−7)又は悪性黒色腫(MelJuso)細胞の接種から数週間後のマウスの肺における肉眼で見えない転移性腫瘍病変の定量は、TPTE siRNAで一過性にトランスフェクトした腫瘍細胞を受容した動物において腫瘍負荷の100〜1000倍の低下を明らかにした(図5b)。
TPTEの強い前遊走及び転移促進作用が腫瘍の転移拡大に関連するかどうかを評価した。このために、十分に特性決定されたコホートからの34名の乳癌患者から独立して収集された試料(Ahr,A.et al.,Lancet 359,131−132(2002))及び24の非小細胞肺癌標本をリアルタイムRT−PCRによってTPTE発現に関して分類した。TPTE発現と腫瘍病期又は分化グレード分類の間で有意な相関はなかった。しかし、TPTE陽性腫瘍は、診断の時点でTPTE陰性原発腫瘍(37%及び0%)よりも有意に局所的なリンパ行性転移(76%)及び遠隔転移(21%)を示した(表2a)。CXCR4発現も、様々な癌についての転移予測マーカーである。それ故、同じセットの試料をCXCR4発現に関して試験した。実際に、CXCR4陽性癌(n=23)は、CXCR4陰性癌(3%)と比較して有意に高い割合の遠隔転移(26%)を示した。重要な点として、TPTE発現とCXCR4発現は相関せず、両方の分子は独立した転移予測因子である(図5c)。TPTEとCXCR4の複合発現を有する癌は極めて高い転移率(60%)を示すが、TPTE、CXCR4のいずれか又は両方の分子を欠く腫瘍はより一層低い転移の危険度を示し(2%、p<0.00005、表2c)、両方の分子の共発現が、癌、特に乳癌及び肺癌、の転移拡大のために重要であることを示唆している。
Claims (40)
- 患者において癌、癌の転移挙動及び/又は癌の再発の存在を診断する、観察する及び/又は予後判定するための方法であって、前記患者から単離された生物学的試料中のTPTEの発現のレベルを定量的及び/又は定性的に測定すること、及び前記患者から単離された生物学的試料中のCXCR4の発現のレベルを定量的及び/又は定性的に測定することを含む方法。
- 癌を有していない、癌の危険性がない、癌の転移がない、癌の転移の危険性がない、癌の再発がない及び/又は癌の再発の危険性がない被験者における発現のレベルに比べて上昇しているTPTEの発現のレベル及びCXCR4の発現のレベルが、癌又は癌の潜在的可能性、癌の転移挙動又は癌の転移挙動の潜在的可能性、及び/又は癌の再発又は癌の再発の潜在的可能性についての指標である、請求項1に記載の方法。
- 前記TPTEの発現レベルの定量的及び/又は定性的測定が、患者から単離された生物学的試料において、
(i)(a)配列番号1、2、3、4、5、6及び7からなる群より選択される核酸配列、その部分又は誘導体を含む核酸、
(b)ストリンジェント条件下で(a)の核酸とハイブリダイズする核酸、
(c)(a)又は(b)の核酸に対して縮重性がある核酸、及び
(d)(a)、(b)又は(c)の核酸に相補的である核酸
からなる群より選択される核酸を検出する又は核酸の量を測定すること、及び/又は
(ii)(i)の下にある核酸によってコードされるタンパク質又はペプチド若しくはその部分又は誘導体を検出する又はその量を測定すること、及び/又は
(iii)(ii)の下にあるタンパク質又はペプチド若しくはその部分又は誘導体に特異的な抗体を検出する又は抗体の量を測定すること、及び/又は
(iv)場合によりMHC分子との複合体中で、(ii)の下にあるタンパク質又はペプチド若しくはその部分又は誘導体に特異的なTリンパ球を検出する又はTリンパ球の量を測定すること
を含む、請求項1又は2に記載の方法。 - 前記CXCR4の発現レベルの定量的及び/又は定性的測定が、患者から単離された生物学的試料において、
(i)(a)配列番号47及び48からなる群より選択される核酸配列、その部分又は誘導体を含む核酸、
(b)ストリンジェント条件下で(a)の核酸とハイブリダイズする核酸、
(c)(a)又は(b)の核酸に対して縮重性がある核酸、及び
(d)(a)、(b)又は(c)の核酸に相補的である核酸
からなる群より選択される核酸を検出する又は核酸の量を測定すること、及び/又は
(ii)(i)の下にある核酸によってコードされるタンパク質又はペプチド若しくはその部分又は誘導体を検出する又はその量を測定すること、及び/又は
(iii)(ii)の下にあるタンパク質又はペプチド若しくはその部分又は誘導体に特異的な抗体を検出する又は抗体の量を測定すること、及び/又は
(iv)場合によりMHC分子との複合体中で、(ii)の下にあるタンパク質又はペプチド若しくはその部分又は誘導体に特異的なTリンパ球を検出する又はTリンパ球の量を測定すること
を含む、請求項1〜3のいずれかに記載の方法。 - 前記TPTEの発現レベルの定量的及び/又は定性的測定における(i)の下での核酸が、配列番号8、9、10、11、12、13及び14からなる群より選択されるアミノ酸配列、その部分又は誘導体を含むタンパク質又はペプチドをコードする核酸配列を含む、及び/又は前記TPTEの発現レベルの定量的及び/又は定性的測定における(ii)の下でのタンパク質又はペプチドが、配列番号8、9、10、11、12、13及び14からなる群より選択されるアミノ酸配列、その部分又は誘導体を含む、請求項3又は4に記載の方法。
- 前記CXCR4の発現レベルの定量的及び/又は定性的測定における(i)の下での核酸が、配列番号49及び50からなる群より選択されるアミノ酸配列、その部分又は誘導体を含むタンパク質又はペプチドをコードする核酸配列を含む、及び/又は前記CXCR4の発現レベルの定量的及び/又は定性的測定における(ii)の下でのタンパク質又はペプチドが、配列番号49及び50からなる群より選択されるアミノ酸配列、その部分又は誘導体を含む、請求項4又は5に記載の方法。
- 前記核酸の検出又は核酸の量の測定が、
(i)生物学的試料を核酸に特異的に結合する作用物質と接触させること、及び
(ii)作用物質と核酸の間の複合体の形成を検出する又は複合体の量を測定すること
を含む、請求項3〜6のいずれかに記載の方法。 - 前記タンパク質又はペプチド若しくはその前記部分又は誘導体の検出又はその量の測定が、
(i)生物学的試料を、タンパク質又はペプチド若しくはその部分又は誘導体に特異的に結合する作用物質と接触させること、及び
(ii)作用物質とタンパク質又はペプチド若しくはその部分又は誘導体との間の複合体の形成を検出する又は複合体の量を測定すること
を含む、請求項3〜6のいずれかに記載の方法。 - 前記抗体の検出又は抗体の量の測定が、
(i)生物学的試料を抗体に特異的に結合する作用物質と接触させること、及び
(ii)作用物質と抗体の間の複合体の形成を検出する又は複合体の量を測定すること
を含む、請求項3〜6のいずれかに記載の方法。 - 前記Tリンパ球の検出又はTリンパ球の量の測定が、
(i)生物学的試料をTリンパ球に特異的に結合する作用物質と接触させること、及び
(ii)作用物質とTリンパ球の間の複合体の形成を検出する又は複合体の量を測定すること
を含む、請求項3〜6のいずれかに記載の方法。 - 核酸に特異的に結合する作用物質が、前記核酸に特異的にハイブリダイズするオリゴヌクレオチド又はポリヌクレオチドである、請求項7に記載の方法。
- タンパク質又はペプチド若しくはその部分又は誘導体に特異的に結合する作用物質が、前記タンパク質又はペプチド若しくはその前記部分又は誘導体に特異的に結合する抗体である、請求項8に記載の方法。
- 抗体に特異的に結合する作用物質が、前記抗体に特異的に結合するタンパク質又はペプチドである、請求項9に記載の方法。
- Tリンパ球に特異的に結合する作用物質が、Tリンパ球がそれに対して特異的であるタンパク質又はペプチド若しくはその部分又は誘導体とMHC分子との間の複合体を提示する細胞である、請求項10に記載の方法。
- 前記観察が、前記癌、前記癌の転移挙動及び/又は前記癌の再発の存在の退行、経過又は発症を測定することを含む、請求項1〜14のいずれかに記載の方法。
- 1番目の時点で1番目の試料中の発現レベルを測定し、2番目の時点でさらなる試料中の発現レベルを測定して、2つの試料の比較を行うことを含む、請求項15に記載の方法。
- 前記患者が、癌、癌の転移及び/又は癌の再発を有する、又は癌の罹患、癌の転移及び/又は癌の再発が疑われる、又は危険性を有する、請求項1〜16のいずれかに記載の方法。
- 前記作用物質が検出可能に標識されている、請求項7〜17のいずれかに記載の方法。
- 前記生物学的試料が体液及び/又は体組織を含む、請求項1〜18のいずれかの記載の方法。
- 患者から単離された生物学的試料においてTPTEの発現のレベルを定量的及び/又は定性的に測定するための手段及びCXCR4の発現のレベルを定量的及び/又は定性的に測定するための手段を含むキット。
- 患者から単離された生物学的試料において、前記TPTEの発現レベルを定量的及び/又は定性的に測定するための手段が、
(i)(a)配列番号1、2、3、4、5、6及び7からなる群より選択される核酸配列、その部分又は誘導体を含む核酸、
(b)ストリンジェント条件下で(a)の核酸とハイブリダイズする核酸、
(c)(a)又は(b)の核酸に対して縮重性がある核酸、及び
(d)(a)、(b)又は(c)の核酸に相補的である核酸
からなる群より選択される核酸を検出する又は核酸の量を測定するための手段、及び/又は
(ii)(i)の下にある核酸によってコードされるタンパク質又はペプチド若しくはその部分又は誘導体を検出する又はその量を測定するための手段、及び/又は
(iii)(ii)の下にあるタンパク質又はペプチド若しくはその部分又は誘導体に特異的な抗体を検出する又は抗体の量を測定するための手段、及び/又は
(iv)場合によりMHC分子との複合体中で、(ii)の下にあるタンパク質又はペプチド若しくはその部分又は誘導体に特異的なTリンパ球を検出する又はTリンパ球の量を測定するための手段
からなる群より選択される、請求項20に記載のキット。 - 患者から単離された生物学的試料において、前記CXCR4の発現レベルを定量的及び/又は定性的に測定するための手段が、
(i)(a)配列番号47及び48からなる群より選択される核酸配列、その部分又は誘導体を含む核酸、
(b)ストリンジェント条件下で(a)の核酸とハイブリダイズする核酸、
(c)(a)又は(b)の核酸に対して縮重性がある核酸、及び
(d)(a)、(b)又は(c)の核酸に相補的である核酸
からなる群より選択される核酸を検出する又は核酸の量を測定するための手段、及び/又は
(ii)(i)の下にある核酸によってコードされるタンパク質又はペプチド若しくはその部分又は誘導体を検出する又はその量を測定するための手段、及び/又は
(iii)(ii)の下にあるタンパク質又はペプチド若しくはその部分又は誘導体に特異的な抗体を検出する又は抗体の量を測定するための手段、及び/又は
(iv)場合によりMHC分子との複合体中で、(ii)の下にあるタンパク質又はペプチド若しくはその部分又は誘導体に特異的なTリンパ球を検出する又はTリンパ球の量を測定するための手段
からなる群より選択される、請求項20又は21に記載のキット。 - 前記TPTEの発現レベルの定量的及び/又は定性的測定における(i)の下での核酸が、配列番号8、9、10、11、12、13及び14からなる群より選択されるアミノ酸配列、その部分又は誘導体を含むタンパク質又はペプチドをコードする核酸配列を含む、及び/又は前記TPTEの発現レベルの定量的及び/又は定性的測定における(ii)の下でのタンパク質又はペプチドが、配列番号8、9、10、11、12、13及び14からなる群より選択されるアミノ酸配列、その部分又は誘導体を含む、請求項21又は22に記載のキット。
- 前記CXCR4の発現レベルの定量的及び/又は定性的測定における(i)の下での核酸が、配列番号49及び50からなる群より選択されるアミノ酸配列、その部分又は誘導体を含むタンパク質又はペプチドをコードする核酸配列を含む、及び/又は前記CXCR4の発現レベルの定量的及び/又は定性的測定における(ii)の下でのタンパク質又はペプチドが、配列番号49及び50からなる群より選択されるアミノ酸配列、その部分又は誘導体を含む、請求項22又は23に記載のキット。
- 前記核酸を検出する又は前記核酸の量を測定するための前記手段が、核酸に特異的に結合する作用物質を含む、請求項21〜24のいずれかに記載のキット。
- 前記タンパク質又はペプチド若しくはその部分又は誘導体を検出する又はその量を測定するための前記手段が、タンパク質又はペプチド若しくはその部分又は誘導体に特異的に結合する作用物質を含む、請求項21〜25のいずれかに記載のキット。
- 前記抗体を検出する又は前記抗体の量を測定するための前記手段が、抗体に特異的に結合する作用物質を含む、請求項21〜26のいずれかに記載のキット。
- 前記Tリンパ球を検出する又は前記Tリンパ球の量を測定するための前記手段が、Tリンパ球に特異的に結合する作用物質を含む、請求項21〜27のいずれかに記載のキット。
- 核酸に特異的に結合する作用物質が、前記核酸に特異的にハイブリダイズするオリゴヌクレオチド又はポリヌクレオチドである、請求項25に記載のキット。
- タンパク質又はペプチド若しくはその部分又は誘導体に特異的に結合する作用物質が、前記タンパク質又はペプチド若しくはその前記部分又は誘導体に特異的に結合する抗体である、請求項26に記載のキット。
- 抗体に特異的に結合する作用物質が、前記抗体に特異的に結合するタンパク質又はペプチドである、請求項27に記載のキット。
- Tリンパ球に特異的に結合する作用物質が、Tリンパ球がそれに対して特異的であるタンパク質又はペプチド若しくはその部分又は誘導体とMHC分子との間の複合体を提示する細胞である、請求項28に記載のキット。
- 患者に投与したとき、(i)TPTEの発現又は活性を低下させる又は阻害する上で有効である及び/又はTPTEに結合し、腫瘍破壊又は腫瘍阻害活性を有する作用物質、及び(ii)CXCR4の発現又は活性を低下させる又は阻害する上で有効である及び/又はCXCR4に結合し、腫瘍破壊又は腫瘍阻害活性を有する作用物質を含む医薬組成物。
- 作用物質が、TPTE及び/又はCXCR4をコードする核酸と選択的にハイブリダイズするアンチセンス核酸である、請求項33の医薬組成物。
- 作用物質がセンスRNA鎖とアンチセンスRNA鎖を含むsiRNAであり、センスRNA鎖とアンチセンスRNA鎖がRNA二本鎖を形成し、及びセンスRNA鎖が、TPTE mRNA内及び/又はCXCR4 mRNA内の約19〜約25個の連続ヌクレオチドの標的配列と実質的に同一のヌクレオチド配列を含む、請求項33に記載の医薬組成物。
- 作用物質がTPTE及び/又はCXCR4に選択的に結合する抗体である、請求項33に記載の医薬組成物。
- (I)(i)TPTE又はその部分、
(ii)TPTE又はその部分をコードする核酸、
(iii)TPTE又はその部分に結合する抗体、
(iv)TPTEをコードする核酸と特異的にハイブリダイズするアンチセンス核酸、
(v)TPTEに対するsiRNA、
(vi)TPTE又はその部分を発現する宿主細胞、及び
(vii)TPTE又はその部分とMHC分子との間の単離複合体
からなる群より選択される1又はそれ以上の成分、及び
(II)(i)CXCR4又はその部分、
(ii)CXCR4又はその部分をコードする核酸、
(iii)CXCR4又はその部分に結合する抗体、
(iv)CXCR4をコードする核酸と特異的にハイブリダイズするアンチセンス核酸、
(v)CXCR4に対するsiRNA、
(vi)CXCR4又はその部分を発現する宿主細胞、及び
(vii)CXCR4又はその部分とMHC分子との間の単離複合体
からなる群より選択される1又はそれ以上の成分
を含有する医薬組成物。 - 抗体が治療物質に結合している、請求項36又は37に記載の医薬組成物。
- 請求項33〜38のいずれかに記載の医薬組成物を投与することを含む、癌、癌の転移又は癌の再発を治療する方法。
- 癌が、肺腫瘍、乳房腫瘍、前立腺腫瘍、黒色腫、結腸腫瘍、胃腫瘍、膵腫瘍、ENT腫瘍、腎細胞癌又は子宮頸癌、結腸癌又は乳癌である、請求項35に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06021434A EP1911851A1 (en) | 2006-10-12 | 2006-10-12 | Compositions and methods for therapy and diagnosis of cancer and cancer metastasis |
EP06021434.3 | 2006-10-12 | ||
PCT/EP2007/008777 WO2008043525A1 (en) | 2006-10-12 | 2007-10-09 | Compositions and methods for therapy and diagnosis of cancer and cancer metastasis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010505428A true JP2010505428A (ja) | 2010-02-25 |
JP5732195B2 JP5732195B2 (ja) | 2015-06-10 |
Family
ID=37735242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009531763A Active JP5732195B2 (ja) | 2006-10-12 | 2007-10-09 | 癌及び癌転移の治療と診断のための組成物及び方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20090253775A1 (ja) |
EP (3) | EP1911851A1 (ja) |
JP (1) | JP5732195B2 (ja) |
CN (1) | CN101522918A (ja) |
CA (1) | CA2660810C (ja) |
NZ (1) | NZ576082A (ja) |
WO (1) | WO2008043525A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2184273A1 (de) * | 2008-11-05 | 2010-05-12 | Bayer CropScience AG | Halogen-substituierte Verbindungen als Pestizide |
WO2018184768A1 (en) * | 2017-04-03 | 2018-10-11 | Qiagen Gmbh | Method for analyzing the expression of one or more biomarker rna molecules |
CN114058623B (zh) * | 2020-08-06 | 2023-12-12 | 中国科学院化学研究所 | 一种核酸适体识别并结合整合素α3亚基及其相关功能 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026205A2 (de) * | 2003-09-10 | 2005-03-24 | Ganymed Pharmaceuticals Ag | Differentiell in tumoren exprimierte genprodukte und deren verwendung |
WO2006091112A1 (en) * | 2005-02-22 | 2006-08-31 | Genesis Reasearch And Development Corporation Limited | Compositions for the delivery of rna interference molecules and methods for their use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
JP5500750B2 (ja) | 2000-03-30 | 2014-05-21 | ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ | Rna干渉のrna配列特異的メディエータ |
-
2006
- 2006-10-12 EP EP06021434A patent/EP1911851A1/en not_active Withdrawn
-
2007
- 2007-10-09 CA CA2660810A patent/CA2660810C/en active Active
- 2007-10-09 CN CNA2007800376906A patent/CN101522918A/zh active Pending
- 2007-10-09 JP JP2009531763A patent/JP5732195B2/ja active Active
- 2007-10-09 NZ NZ576082A patent/NZ576082A/en not_active IP Right Cessation
- 2007-10-09 EP EP07818850.5A patent/EP2069538B1/en active Active
- 2007-10-09 EP EP11009021A patent/EP2474623A1/en not_active Withdrawn
- 2007-10-09 WO PCT/EP2007/008777 patent/WO2008043525A1/en active Application Filing
-
2009
- 2009-04-08 US US12/420,612 patent/US20090253775A1/en not_active Abandoned
-
2013
- 2013-03-14 US US13/826,030 patent/US9061007B2/en active Active
-
2015
- 2015-05-14 US US14/712,233 patent/US20150247206A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026205A2 (de) * | 2003-09-10 | 2005-03-24 | Ganymed Pharmaceuticals Ag | Differentiell in tumoren exprimierte genprodukte und deren verwendung |
WO2006091112A1 (en) * | 2005-02-22 | 2006-08-31 | Genesis Reasearch And Development Corporation Limited | Compositions for the delivery of rna interference molecules and methods for their use |
Non-Patent Citations (3)
Title |
---|
JPN6012056054; Cancer Letters Vol.238, 200607, pp.30-41 * |
JPN6012056055; Molecular Cloning, A Laboratory Manual, 3rd. Ed. Vol.2, 2001, 10.47 * |
JPN6012056057; Current Pharmaceutical Design Vol.10, 2004, pp.1245-1259 * |
Also Published As
Publication number | Publication date |
---|---|
CA2660810C (en) | 2018-03-06 |
US9061007B2 (en) | 2015-06-23 |
AU2007306598A1 (en) | 2008-04-17 |
EP2474623A1 (en) | 2012-07-11 |
NZ576082A (en) | 2012-05-25 |
US20150247206A1 (en) | 2015-09-03 |
EP2069538A1 (en) | 2009-06-17 |
CA2660810A1 (en) | 2008-04-17 |
JP5732195B2 (ja) | 2015-06-10 |
US20130224214A1 (en) | 2013-08-29 |
EP1911851A1 (en) | 2008-04-16 |
EP2069538B1 (en) | 2015-07-08 |
CN101522918A (zh) | 2009-09-02 |
US20090253775A1 (en) | 2009-10-08 |
WO2008043525A1 (en) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5913547B2 (ja) | 診断および治療のための腫瘍関連抗原の同定 | |
US20120252022A1 (en) | Methods and compositions for the diagnosis and treatment of thyroid cancer | |
WO2008011519A2 (en) | Amigo-2 inhibitors for treating, diagnosing or detecting cancer | |
US20120165390A1 (en) | Compositions and Methods for Therapy and Diagnosis of Cancer | |
US20150247206A1 (en) | Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis | |
US20110027297A1 (en) | Methods Involving MS4A12 and Agents Targeting MS4A12 for Therapy, Diagnosis and Testing | |
AU2007306598B2 (en) | Compositions and methods for therapy and diagnosis of cancer and cancer metastasis | |
US9150929B2 (en) | Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101008 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121030 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130123 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130426 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130613 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140204 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140313 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140507 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150130 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150324 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150413 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5732195 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |